What is ARA-290 (15mg) Peptides
ARA-290 is a non-erythropoietic peptide derived from erythropoietin, designed to retain the tissue-protective and anti-inflammatory properties of erythropoietin without its hematopoietic effects. This makes ARA-290 a promising candidate for research in various medical conditions where inflammation and tissue damage are prevalent.One of the key areas of interest is its potential in treating neuropathic pain and metabolic disorders. In patients with type 2 diabetes, ARA-290 has shown promise in improving metabolic control and alleviating neuropathic symptoms, suggesting a role in both metabolic and nerve health.
Peptide Information
Property Value
Peptide Sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Molecular Formula C51H84N16O21
Molecular Weight 1257.3 g/mol
CAS Number 1208243-50-8
PubChem CID 91810664
Synonyms Cibinetide, 1208243-50-8, ARA290, PHBSP, ARA 290
Is it legal to buy ARA-290 (15mg) Peptide
The legal status of buying ARA-290 depends significantly on your location and how the product is marketed, but generally, it is not legally approved for human commercial use or over-the-counter sale. Here is how the regulations break down. But you can order directly from us without any necessary paper works.
How many injections do i take a month using ARA-290 (15mg) Peptide
In formal scientific literature and clinical trials, the standard dosing protocol for ARA-290 is one subcutaneous injection daily for 28 to 84 days (1 to 3 months). Because your vial contains 15mg, the total number of injections you get out of it—and how many vials you need per month—depends entirely on the daily dosage used.
1. The Standard Clinical Protocol (4 mg / Day)
In Phase II clinical trials for small fiber neuropathy and diabetes, the established daily dose is 4 mg per day.
Frequency: 1 injection every day (30 injections per month).
Vial Lifespan: A 15mg vial will only last you 3.75 days at this dose.
Monthly Requirement: To complete a full month at the standard clinical dose, you would need 8 vials of 15mg per month.
Benefits of using ARA-290 (15mg) Peptide
In scientific research and clinical trials, ARA-290 (also known as Cibinetide) is studied primarily for its unique ability to turn off chronic inflammation and stimulate nerve repair without triggering the dangerous side effects of its parent molecule, erythropoietin (EPO).
Because your vial is 15mg, it represents a multi-dose supply used in these research settings to What’s the difference between ARA-290 (15mg) Peptides investigate the following primary benefits:
1. Relief from Small Fiber Neuropathy (SFN)
The most extensively researched benefit of ARA-290 is its impact on small fiber neuropathy—a painful condition affecting the tiny nerve endings in the skin, often caused by diabetes, sarcoidosis, or autoimmune diseases.